![Richard Gregory](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Richard Gregory
Directeur/Membre du Conseil chez
CANBRIDGE PHARMACEUTICALS INC.
Fortune : - $ au 31/05/2026
Profil
Richard James Gregory is currently an Independent Non-Executive Director at CANbridge Pharmaceuticals Inc. since 2020.
Former positions include Independent Director at ProMIS Neurosciences, Inc. from 2016 to 2023; Chief Scientific Officer & Director at Canbridge Pharmaceuticals, Inc. (United States); Independent Director at Homology Medicines, Inc.; Chief Scientific Officer & Executive VP-Research at ImmunoGen, Inc. from 2015 to 2019; and Head-Research & Development at Genzyme Corp.
from 2011 to 2014.
Education includes a doctorate from the University of Massachusetts conferred in 1986 and an undergraduate degree from Virginia Polytechnic Institute & State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/01/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Richard Gregory
| Sociétés | Poste | Début |
|---|---|---|
| CANBRIDGE PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 21/04/2020 |
Anciens postes connus de Richard Gregory
| Sociétés | Poste | Fin |
|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Directeur/Membre du Conseil | 27/04/2023 |
| IMMUNOGEN, INC. | Directeur Technique/Scientifique/R&D | 30/08/2019 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Directeur Technique/Scientifique/R&D | 01/01/2014 |
Canbridge Pharmaceuticals, Inc. (United States)
 Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Operates as a biopharmaceutical company which research, development and commercialization of transformative therapies | Directeur Technique/Scientifique/R&D | - |
| Q32 BIO INC. | Directeur/Membre du Conseil | - |
Formation de Richard Gregory
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
75
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
ProMIS Neurosciences, Inc.
 ProMIS Neurosciences, Inc. BiotechnologyHealth Technology Discovers and develops precision medicine solutions for the treatment of neurodegenerative & misfolded protein diseases | Health Technology |
University of Massachusetts
 University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Virginia Polytechnic Institute & State University
 Virginia Polytechnic Institute & State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage genetic medicines company | Health Technology |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Operates as a biopharmaceutical company which research, development and commercialization of transformative therapies | Health Technology |
CANbridge Pharmaceuticals Inc.
 CANbridge Pharmaceuticals Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
